Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers ; volume:10 ; number:1 ; day:2 ; month:11 ; year:2024 ; pages:1-8 ; date:12.2024
npj Breast cancer ; 10, Heft 1 (2.11.2024), 1-8, 12.2024
- Urheber
-
Hilbers, Florentine S.
Poncet, Coralie
Tryfonidis, Konstantinos
Viale, Giuseppe
Delaloge, Suzette
Pierga, Jean-Yves
Brain, Etienne G. C.
Rubio, Isabel T.
Thompson, Alastair M.
Rutgers, Emiel J. T.
Piccart, Martine J.
Veer, Laura J. van ’t
Cardoso, Fatima
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-024-00670-2
- URN
-
urn:nbn:de:101:1-2501212125103.217606725291
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hilbers, Florentine S.
- Poncet, Coralie
- Tryfonidis, Konstantinos
- Viale, Giuseppe
- Delaloge, Suzette
- Pierga, Jean-Yves
- Brain, Etienne G. C.
- Rubio, Isabel T.
- Thompson, Alastair M.
- Rutgers, Emiel J. T.
- Piccart, Martine J.
- Veer, Laura J. van ’t
- Cardoso, Fatima
- SpringerLink (Online service)
Ähnliche Objekte (12)
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases